Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.
Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI. Garritano S, et al. Among authors: palmero ei. Hum Mutat. 2010 Feb;31(2):143-50. doi: 10.1002/humu.21151. Hum Mutat. 2010. PMID: 19877175
Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C, Carneiro ASB, de Oliveira Lessa AC, Lacerda DC, Paiva CE, Zorzetto MMC, de Freitas AJA, Santana IVV, de Oliveira MA, Palmero EI, Marques MMC, Reinert T. de Pádua Souza C, et al. Among authors: palmero ei. Breast Cancer Res Treat. 2023 Nov;202(1):57-65. doi: 10.1007/s10549-023-07011-0. Epub 2023 Aug 14. Breast Cancer Res Treat. 2023. PMID: 37578666 Free PMC article. Clinical Trial.
RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors.
Ramos CRN, Oliveira RJS, Rosa MN, Pereira AS, de Abreu RBV, van Helvoort Lengert A, Reis RM, Silva VAO, Palmero EI, Melendez ME. Ramos CRN, et al. Among authors: palmero ei. Curr Cancer Drug Targets. 2023;23(11):900-909. doi: 10.2174/1568009623666230418101511. Curr Cancer Drug Targets. 2023. PMID: 37076963
BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
Mazzonetto P, Milanezi F, D'Andrea M, Martins S, Monfredini PM, Dos Santos Silva J, Perrone E, Villela D, Schnabel B, Nakano V, Palmero EI, Braggio E, Cavalcanti TL, Guida G, Migliavacca MP, Scapulatempo-Neto C, Zalcberg I. Mazzonetto P, et al. Among authors: palmero ei. Breast Cancer Res Treat. 2023 May;199(1):127-136. doi: 10.1007/s10549-023-06892-5. Epub 2023 Mar 7. Breast Cancer Res Treat. 2023. PMID: 36881271
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P. Palmero EI, et al. Cancer Lett. 2008 Mar 8;261(1):21-5. doi: 10.1016/j.canlet.2007.10.044. Epub 2008 Jan 11. Cancer Lett. 2008. PMID: 18248785
79 results